隶属于 full gain pharmaceutical ltd.
相关临床试验
94
35 进行中
药物批准
10
批准总数
监管机构
1
监管机构数
成立时间
2002
进行中（未招募）
14
14.9%
已完成
22
23.4%
尚未招募
21
22.3%
招募中
25
26.6%
Unknown
12
12.8%
- Sunshine Guojian reported first-half 2026 total operating revenue of RMB866 million, up 34.84% year-on-year, with net profit surging 95.10% to RMB371 million. - Two self-developed antibodies, Yisaituo (Amdokitug) for plaque psoriasis and Yisaina (Anflekitug) for acute gouty arthritis, received NMPA marketing approval in 2026. - The anti-IL-4Rα antibody (code 611) for atopic dermatitis had its NDA accepted in February 2026, with multiple Phase III trials completing enrollment or meeting primary endpoints. - The Pfizer-partnered PF-08634404 (SSGJ-707) program has launched nine global multicenter trials across solid tumor indications including NSCLC and colorectal cancer.
- The RELAX study involving 172 patients showed Xenopax achieved a 64.5% overall response rate at day 28 and 82.6% at any time in steroid-refractory acute graft-versus-host disease patients. - Xenopax demonstrated lower infection rates (37.8%) compared to best available treatments (60.8%) while maintaining comparable survival outcomes with 68% two-year overall survival. - The humanized IL-2 receptor antagonist showed particular efficacy in severe cases, with 81.2% response rates in grade III-IV patients and superior cost-effectiveness compared to existing therapies.
